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Abstract
Background: The immune system plays a fundamental role in development during pregnancy and early life.
Alterations in circulating maternal and neonatal immune mediators have been associated with pregnancy complications
as well as susceptibility to autoimmune and neurodevelopmental conditions in later life. Evidence suggests that the
immune system in adults not only responds to environmental stimulation but is also under strong genetic control.
Methods: This is the first genetic study of > 700 mother-infant pairs to analyse the circulating levels of 22 maternal
mid-gestational serum-derived and 42 neonatal bloodspot-derived immune mediators (cytokines/chemokines) in the
context of maternal and fetal genotype. We first estimated the maternal and fetal genome-wide SNP-based heritability
(h2g) for each immune molecule and then performed genome-wide association studies (GWAS) to identify specific loci
contributing to individual immune mediators. Finally, we assessed the relationship between genetic immune
determinants and ASD outcome.
Results: We show maternal and neonatal cytokines/chemokines displaying genetic regulation using independent
methodologies. We demonstrate that novel fetal loci for immune function independently affect the physiological
levels of maternal immune mediators and vice versa. The cross-associated loci are in distinct genomic regions
compared with individual-specific immune mediator loci. Finally, we observed an interaction between increased
IL-8 levels at birth, autism spectrum disorder (ASD) status, and a specific maternal genotype.
Conclusions: Our results suggest that maternal and fetal genetic variation influences the immune system during
pregnancy and at birth via distinct mechanisms and that a better understanding of immune factor determinants
in early development may shed light on risk factors for developmental disorders.
Keywords: Cytokines, Chemokines, Immune system, Maternal and fetal genetics, GWAS, SNP-based heritability,
Early brain development, Autism
Background
Women experience dramatic changes in immune system
status during pregnancy. Tolerance for fetal-placental anti-
gens allowing for healthy development of the fetus must be
balanced with the ability of the mother to fight infections.
Further, immune dysregulation during pregnancy can lead
to outcomes such as preeclampsia, fetal growth retardation,
and miscarriage [1, 2]. However, little is known about
inter-individual differences in immune status during preg-
nancy. Similarly, immune protection in early infancy is
thought to be accomplished by a combination of maternal
transfer and fetal production of soluble immune molecules,
but the extent of maternal contribution has not been
worked out for many immune molecules.
Among the soluble molecules that mediate the immune
response, cytokines and chemokines are particularly im-
portant for regulating inflammation, immune cell prolifer-
ation and differentiation, and for influencing the
progression of some chronic inflammatory conditions [3,
4]. Cytokines are small peptides involved in most phases
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of immune response, and chemokines are specific cyto-
kines that are also important in controlling white blood
cell trafficking and attracting cells to an infection site.
Immune responses to environmental stimuli (e.g., in-
fections) are tightly regulated by genetics. Several studies
have shown genetic variation associated with RNA or
protein levels of immune mediators [5–7] and substan-
tial heritability of immune cell counts [6]. Moreover, a
recent study [8] identified 27 specific loci associated with
circulating levels of 41 cytokines/chemokines, mainly in
genes that encode the proteins and/or their receptors,
and that were also associated with inflammatory and
autoimmune diseases. However, despite this strong evi-
dence for genetic control of immune system status, no
study has analysed the genetic regulation of maternal
immune mediator levels during pregnancy, neonatal
levels at birth, or the intersection of genetic determi-
nants of either with chronic disorders.
To fill the gaps in our current understanding of genetic
regulation of the immune system during pregnancy and at
birth, we first hypothesize that maternal mid-gestational
mediator levels will be regulated by maternal genetics,
some of which could be unique to pregnancy. Second, we
define two possible scenarios for neonatal immune system
status. At birth, the neonatal immune system might be at
least partially determined by the mother; so, we
hypothesize that maternal genetics could regulate not only
maternal mediator levels but also contribute to neonatal
mediator levels. In the second scenario, we hypothesize
that the neonatal genome would exert independent influ-
ence on neonatal mediator levels.
Increasing evidence shows that during pregnancy, fetal
genetics also contributes to different aspects of maternal
physiology, such as blood pressure, gestational diabetes,
metabolism, and preeclampsia [9–11]. We previously
showed that some maternal circulating toxicant levels in
pregnancy are in part regulated by fetal genetics [12].
However, there has been no study looking at the potential
fetal genetic influences on maternal immune status during
pregnancy. Thus, we also hypothesize that genetic vari-
ation in the fetus and placenta might influence the
mother’s immune system function during pregnancy.
Understanding patterns of genetic regulation of circulating
maternal and neonatal immune mediators might elucidate
important mechanisms for immune system status and
disease susceptibilities. Beyond their classical roles in im-
mune function, recent evidence suggests that some cyto-
kines show pleiotropic effects in the central nervous system
(CNS), acting as neuromodulators, growth and survival fac-
tors [13], neurodevelopmental organizers [14], and ultim-
ately influencing behavior and cognition. Animal models
[15] of maternal immune activation (MIA) during preg-
nancy demonstrate behavioral abnormalities in offspring,
proposed to be mediated via cytokines [16–18]. In addition,
peripheral abnormalities of circulating cytokine levels have
been observed in individuals affected by neuropsychiatric
disorders, such as major depression, bipolar disorder, schizo-
phrenia, and autism spectrum disorder (ASD) [19–23].
Among neurodevelopmental disorders, ASD is thought
to originate in early development. ASD is a highly herit-
able complex disease, with both genetic and non-genetic
risk factors, proposed to include maternal infection [24]
and fever [25, 26] and maternal and neonatal immune
system dysregulation [27–30]. Elevated peripheral cyto-
kine profiles in pregnancy [31] and at birth have been
associated with ASD diagnosis in childhood [32, 33]. A
study in our Early Markers for Autism (EMA) maternal
dataset found elevated maternal cytokine levels during
mid-gestation associated with an increased risk of ASD
with intellectual disability [34]. We have also observed ele-
vated levels of cytokines/chemokines in neonatal blood-
spots from ASD-affected children compared to controls.
However, neither our studies nor others implicating im-
mune mediators in ASD have included measurement of
genetics to distinguish inborn from environmentally stim-
ulated variation in immune molecules.
To test our hypotheses, we applied several methodolo-
gies to a large set of maternal and neonatal soluble im-
mune mediators (SIMs), specifically cytokines and
chemokines, in combination with genetic markers in the
EMA cohort, a population-based nested case-control
study of ASD. This dataset utilizes samples from a mater-
nal prenatal screening program and neonatal bloodspots
from the sampled pregnancies to measure genetic and im-
mune molecules (with no direct measurement or record
of infection or illness). (Note that we define the genetic
contribution from the fetus during pregnancy and from
the neonate at birth as ‘fetal genetics’ for consistency of
terminology and to represent the likely timing of genetic
regulation, although the genetic data were collected
shortly after birth). We first estimated heritability to deter-
mine the extent to which an individual’s cytokine/chemo-
kine levels might be genetically regulated. We next
performed genome-wide association identifying specific
contributing loci. We also used several approaches to in-
vestigate whether neonatal cytokines/chemokines might
be influenced by maternal genetic variation and/or mater-
nal cytokines/chemokines could be influenced by fetal
genetic variation. Finally, in order to understand the inter-
section of genetic determinants of maternal and/or fetal
immune function with developmental disorders, we stud-
ied the potential for interaction between an immune me-
diator and genetic variation on ASD outcome.
Methods
Study population and blood sampling
The Early Markers for Autism (EMA) study is a
population-based nested case-control study [35, 36] that
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includes a population of pregnant women (15–20 weeks)
and their babies from Orange, San Diego and Imperial
Counties, California, who were enrolled in the State’s
Prenatal Expanded Alphafetoprotein Screening Program
and delivered a live-born infant in 2000–2003. We used
prenatal (maternal blood) and newborn (neonatal blood
spot) specimens from each mother-baby matching pair.
The offspring outcome of ASD was ascertained from the
client files of two regional centers (RCs) and verified by
study clinician expert review of records according to a
protocol developed by the Metropolitan Atlanta
Developmental Disabilities Surveillance Program, as de-
scribed previously [12, 36]. The controls were randomly
sampled from the birth certificate files after past or
current RC clients had been excluded, matched to ASD
cases by sex, birth month, and birth year [36]. Maternal
blood samples were collected in serum separator tubes at
15–20 weeks gestation and stored as part of Project Baby’s
Breath. Serum was stored in cryovials and cell pellets
stored in SSTs at − 20 °C. Newborn blood spots were
collected on filter paper 1–2 days after birth and stored at
− 20 °C and maintained by the Genetic Disease Screening
Program, California Department of Public Health.
Cytokine and chemokine measurement
Maternal mid-gestational serum concentrations of 22 cy-
tokines and chemokines were determined using a com-
mercially available multiplex bead-based kit (MILLIPLEX
MAP Human Cytokine/Chemokine Kit; Millipore,
Billerica, MA, USA) in accordance with the kit-specific
protocols provided by Millipore and as already described
[34] (see more details in Additional file 1: Supplemental
methods). We measured 16 cytokines and six chemokines
reported in Additional file 2: Table S1. The neonatal levels
of peripheral blood immune markers were extracted from
filter spots as described in Additional file 1: Supplemental
methods and determined using a commercially available,
slightly modified, Luminex multiplex assay. We combined
a Bio-Plex Pro Human Chemokine kit (Bio-Rad, Hercules,
CA) containing a mix of 40 different immune markers
with two individual single-plex beads from the same com-
pany, interleukin (IL)-12p70 and IL-13 (see more details
in Additional file 1: Supplemental methods). We mea-
sured 12 cytokines and 30 chemokines reported in
Additional file 2: Table S1. All study procedures were ap-
proved by the institutional review boards of the California
Health and Human Services Agency and Kaiser
Permanente Northern California; it was determined at
UCSF Committee on Human Research that the institution
was not engaged in human subject research.
DNA extraction and genotyping
The QIAGEN QIAamp 96 DNA Blood Kit was used to
extract DNA from a subset of maternal and neonatal
blood samples and the Invitrogen Quant-iT DNA Assay
Kit to measure the DNA concentration by the biomedical
laboratory at Utah State University, as previously de-
scribed [36]. Maternal and neonatal samples were geno-
typed using the Affymetrix Axiom (Affymetrix 2011) EUR
array (675,000 SNPs across the genome) by the Genomics
Core Facility (GCF) at UCSF, using standard protocols.
Genotype calling was carried out using Affymetrix
Power-Tools (‘Affymetrix Power Tools, Affymetrix
Website’), as previously described [36]. Individual-based
and marker-based quality controls, such as detection of
Mendelian errors and HWE assessment, were performed
with PLINK software [37] as reported in Tsang et al. [36].
Additionally, we extracted only common SNPs
(MAF ≥ 1%). Two high quality datasets were used in our
analysis: the first dataset included 790 maternal samples of
varied ancestry (390 ASD cases, 400 controls) and 629,686
genotyped markers, and the second dataset included 764
neonatal samples (385 ASD cases, 379 controls) and
622,716 genotyped markers. Most of these were related
pairs of maternal-neonatal samples (366 case pairs, 369
control pairs). The maternal dataset was a subset of those
with immune mediator levels reported in Jones et al. [34].
Ancestry analysis
We reported in Traglia et al. [12] the genome-wide
multidimensional scaling (MDS) analysis on high-quality
markers genotyped in mothers and in infants included
in our dataset. The resulting maternal and fetal genetic
matrices included ten principal coordinates that summa-
rized the genetic distance between each maternal and
neonatal sample and that captured 90% and 89% of the
maternal and fetal genetic variance. The distribution of
maternal race/ethnicity based on the birth certificate
was: 42% Hispanic, 35% non-Hispanic Caucasian, 15%
Asian, 3% South Asian, and 3% African American. The
ten maternal and fetal principal coordinates showed
highly significant pairwise correlation with ρ ranging be-
tween 0.82 and 0.95 (Spearman’s test in R 3.2.0 environ-
ment [38] P < 0.05; Additional file 2: Table S2).
Confounding factors for maternal and neonatal immune
mediator levels and linear correlations
We analysed the log-transformed levels of the 22 maternal
and 42 neonatal cytokines and chemokines with > 60% of
values greater than their limit of detection (LOD) defined
as the fluorescence intensity signal 2 standard deviations
above the background signal, as reported in the assay
manual (see Additional file 1: Supplemental methods and
Additional file 2: Table S1). The values below LOD were
replaced with LOD/√2 before the normalization, as re-
ported in Jones et al. [34]. We applied a threshold of 3 or
4 SD from the mean to exclude outliers. The number of
extreme values is reported in Additional file 2: Table S3.
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We analysed the effects of available socio-demographic
and technical covariates on maternal and neonatal im-
mune mediator levels with linear regression models in the
genotyped mothers and infants using R 3.2.0 [38]. In all
the maternal analyses, we included potential confounding
factors that were nominally associated with at least three
maternal immune mediators (P < 0.05), such as maternal
country of birth (USA, Mexico, others), age at
mid-pregnancy (15–45 years old), maternal gestational
days and weight, year of birth, maternal educational at-
tainment (elementary, high school, college, post-graduate),
and maternal genetic ancestry (the first ten coordinates)
(Additional file 3: Figure S1). No variables nominally sig-
nificant in one immune mediator (0.01 < P < 0.05) would
survive multiple testing correction. We also used con-
founding factors associated with at least three neonatal
immune mediators in all the neonatal analyses: offspring
sex, bloodspot time after birth, birth type (spontaneous,
C-section) and weight, birth month and year, maternal
gestational days, maternal and paternal age and educa-
tional attainment, number of prenatal visits, number of
previous live births, assay plate number, neonatal TSH
levels, and neonatal genetic ancestry (1–10 coordinates)
(Additional file 3: Figure S1). In both datasets, we used
offspring ASD status as an additional covariate for quanti-
tative cytokine analyses. The statistics for the residual
levels of each cytokine/chemokine after adjustment for
confounding factors are reported in Additional file 2:
Table S3. Finally, we performed a Shapiro-Wilk normality
test in the R 3.2.0 [38] and reported in Additional file 2:
Table S3. We assessed the linear correlation across 22
maternal cytokines/chemokines and 42 neonatal cyto-
kines/chemokines, including 15 overlapping molecules
measured in both datasets, using the Spearman’s test
implemented in R 3.2.0 ‘corrplot’ package (Fig. 1,
Additional file 2: Tables S4, S5, and S6).
SNP-based heritability and genetic correlation
The final set of maternal and fetal autosomal high qual-
ity markers were used to generate genetic relationship
matrices and calculate SNP-based additive heritability
(h2g) for each maternal and neonatal cytokine/chemo-
kine level with a Restricted Maximum Likelihood
(REML) model implemented in GCTA software [39],
taking into account each specific set of covariates. The
heritability estimation indicates the proportion of the
total phenotypic variance of each cytokine/chemokine
level (σp) accounted for by the genetic variance (σg/σp)
after the exclusion of the effect of the sociodemographic,
ancestry, and case/control status covariates. For each
maternal and neonatal cytokine/chemokine, we used
both maternal and fetal genotypes to assess the
Fig. 1 Linear non-parametric correlation coefficients for 15 overlapping maternal and neonatal cytokines and chemokines. Correlation coefficients
were calculated with Spearman’s test. From weakest to strongest, positive correlation coefficients are represented in a dark grey gradient; negative
correlation coefficients are displayed in a light grey gradient
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heritability for the same cytokine/chemokine. We esti-
mated that our dataset has low power to detect moderate
heritability via the REML approach with GCTA-GREML
Power Calculator [40]. To validate that our approach is
suitable to adjust for population stratification, we used
permutations swapping the phenotype labels for each indi-
vidual 100 times, and we estimated 100 SNP-based per-
muted heritability models for the significantly heritable
immune mediators. Most of the significant maternal and
fetal h2g are in the top 5% of the permuted h
2
g distribu-
tions, and the medians are close to zero, suggesting little
bias from population structure. To determine whether the
significantly heritable maternal and neonatal cytokines/
chemokines shared genetic determinants, we estimated
the genetic correlations (rg) between all possible pairs
within the two datasets using the estimated heritability
(h2g) for each heritable immune mediator in a bivariate
REML [41] model in GCTA software [39] and compared
to the linear correlations across each pair with cor.test() in
the R 3.2.0 ‘stats’ package [38]. We applied Fisher’s z trans-
formation test in the R 3.2.0 environment [38] to assess
significant differences between estimated correlation coef-
ficients (Additional file 2: Table S7). For each cytokine/
chemokine that shows both significant maternal and fetal
heritability, we assessed whether both individuals inde-
pendently contribute to the phenotypic variance. We used
PLINK software [37] and ad hoc bash scripts to compare
each maternal allele to the matching fetal allele for the
same locus (a1a2), and we replaced each maternal geno-
type with the one maternal allele not transmitted to off-
spring and each fetal genotype with one allele not
inherited from the maternal lineage (i.e. for SNP1 mater-
nal a1a2 =AA and fetal a1a2 =AG, A is the maternal
non-transmitted allele and G is the fetal non-maternal al-
lele). We set to 0 (missing genotype) all the SNPs for
which we were unable to determine which allele was ma-
ternal (heterozygous genotype in both mother and off-
spring). This approach may affect the estimate of the
genetic contribution by introducing missing genotypes
among the more common SNPs; thus, we interpret having
significant heritability as meaningful but do not interpret
the estimates as precise. We used PLINK software [37] to
merge the individual pairs and create two new sets of in-
dependent maternal and fetal genotypes (--make-bed). In
the genetic analysis, we wanted to take into account the
haploid status, so we also replaced the sex of all individ-
uals with 1 (male) and the chromosome with X (--upda-
te-sex; --update-chr), and we coded the entire maternal
and fetal independent haploid genomes as male pseudo-X
chromosomes. Two genetic matrices that include only the
maternal-specific alleles and the fetal-specific alleles and
that look like X-chromosomes were generated from
PLINK bed files with GCTA software [39] using a no dos-
age compensation (ND) model (--dc 0; --make-grm-xchr)
and used in cytokine-specific REML models. The ND
model assumes that each allele has a similar effect on the
trait. The genetic relationship matrix (AX) for the X
chromosome is redefined as AX
ND = 1/2AX for male-male
pairs [39]. We applied the Fisher scoring approach as im-
plemented in GCTA (--reml alg 1) for models that did not
converge. It should be noted that the estimates might be
overestimated by using only one haploid genetic matrix in
the model in addition to the low power of moderate herit-
ability detection. Thus, in the text, these estimates are not
considered as ‘heritability’ in a classic sense, but, when sig-
nificant, as an indication of maternal and/or fetal genetic
contribution to the trait.
Genome-wide association study
We performed immune mediator-specific genome-wide
association studies (GWAS) for maternal and fetal SNPs
using a linear model implemented in PLINK software [37]
(--linear) using each specific set of covariates including
ten PCs. To validate that our approach is suitable to adjust
for stratification ‘within’ and ‘across’ populations, we also
performed a meta-analysis of four separate association
tests in homogeneous sub-populations with ten
population-specific PCs and we found consistent results
for top SNPs (Additional file 2: Table S8). We also ex-
tracted the meta-analysis top hits (P < 5 × 10−8) and we
observed a similar trend (Additional file 2: Table S8).
Then, we used the LocusZoom tool [42] to generate re-
gional genomic plots and assess linkage disequilibrium
(LD) among associated SNPs. We use the genome-wide
significance threshold (P < 5 × 10−8) and suggestive thresh-
old (P < 1 × 10−7) to account for approximate independent
common polymorphism testing per GWAS [43, 44]. We
have tested many correlated cytokines/chemokines in re-
lated mothers and offspring; because the tests are not
completely independent, we were unable to calculate the
exact correction for study-wide significance and present
uncorrected P values.
Maternal and fetal contribution to the associated loci
For each cytokine/chemokine that showed a genome-wide
significant maternal and/or fetal locus that is also suggest-
ively associated in the paired individual’s genetics, we
assessed whether the associations were controlled by ma-
ternal and/or fetal genetics. We performed separate linear
regression models including the entire maternal- and/or
fetal-specific set of covariates and the genotypes of mater-
nal- and fetal-associated SNPs (for three maternal im-
mune mediators ~ maternal SNP + fetal SNP +maternal
covariates; for ten neonatal immune mediators ~ fetal
SNP +maternal SNP + fetal covariates), and we assessed
the residual association for maternal and fetal genotypes.
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Offspring ASD outcome association with immune mediators
We tested for differences between the residuals for mater-
nal cytokines/chemokines in mothers of ASD cases and
mothers of controls and for neonatal cytokines/chemokines
in ASD-affected neonates and control neonates with a
two-sample Mann-Whitney Wilcoxon test in R 3.2.0 [38].
Genetic interaction between chemokine levels and ASD
association
We assessed whether genetic determinants associated with
chemokines that showed statistically significant associations
with ASD might drive the association between chemokines
and ASD or show interaction effects. Thus, we selected
each maternal and fetal cytokine-specific top (GW or
suggestive) SNPs for maternal and neonatal chemokines
that are associated with ASD. We included each genotype
in logistic regression models for ASD outcome and we
assessed whether the top SNPs interact with ASD in
cytokine-specific models. We compared the levels of che-
mokines in the individuals with different genotypes for
ASD-interacting SNPs using a two-sample Mann-Whitney
Wilcoxon test in the R 3.2.0 environment [38].
Results
Maternal immune mediators
To assess our ability to identify genetic contributions of
circulating maternal immune mediators, we first ana-
lysed distributions of the log-transformed concentrations
of 16 cytokines and six chemokines surveyed in
mid-gestational maternal blood. We applied adjustment
for potential maternal and neonatal confounding factors,
including offspring ASD outcome (Additional file 3:
Figure S1) to obtain residuals, as we first wanted to as-
sess cytokine/chemokine levels independent of outcome.
After excluding a few extreme residual values for 11 of
22 mediators (outliers < 4% of the total individuals,
mean = 1%; see the ‘Methods’ section), we observed ap-
proximately normally distributed residuals for most
cytokine/chemokine levels (Additional file 2: Table S2).
The observation of unimodal distributions suggested
continuous inter-individual variation in immune medi-
ator levels, rather than distinct classes of individuals
with low/high levels, such as immune-activated vs.
non-activated, within the study population. Thus, all 22
maternal cytokines and chemokines could be used as
quantitative traits for genetic analysis. Some maternal
immune mediators appeared interrelated, as 22 of 231
pairs (9.5%) demonstrated high correlations (ρ > 0.5)
(Additional file 2: Table S4).
High maternal heritability contributes to two maternal
immune mediator levels
We estimated SNP-based maternal heritability for 22
maternal mid-gestational mediator residual levels via
mixed linear model. CXCL10 (or IP-10) and IL-7 were sig-
nificantly regulated by genome-wide maternal SNP effects
(Table 1). The additive maternal polygenic contribution is
estimated to account for 79% and 84% of the total
CXCL10 and IL-7 phenotypic variance (P = 4.4 × 10−3 and
P = 2.1 × 10−3, respectively). We are not able to determine
whether the remaining immune mediators might be herit-
able because our dataset has low power to detect moder-
ate heritability.
Maternal loci associated with maternal mediators
We performed genome-wide association studies (GWAS)
for maternal cytokine/chemokine levels via linear regres-
sion. The maternal cytokines sIL-2Ra and IL-1α and the
chemokine CCL11, were significantly (P < 5 × 10−8) associ-
ated with specific maternal loci (Table 2 and
Additional file 3: Figure S2A–C). CCL11 (or eotaxin-1) is
associated with a low-frequency polymorphism,
rs115463265, which maps on chromosome 3p24.2 in a
lincRNA between THRB and RARB genes encoding re-
ceptors for thyroid hormone. Soluble IL-2Ra is associated
with rs12778662, an intronic variant located in a RNA
binding protein gene (RBM17) and near the gene encod-
ing the IL-2 receptor (IL2RA) on chromosome 10p15.1.
Finally, IL-1α is associated with rs1562064 near the
SMAD1 gene which encodes a member of the bone mor-
phogenetic protein (BMP) pathway on chromosome
4q31.21.
Neonatal immune mediators
We analysed the log-transformed concentrations of 12
cytokines and 30 chemokines measured in neonatal
bloodspots at birth in the genotyped EMA sample. As
reported in Additional file 2: Table S2, 15 out of 42
Table 1 SNP-based maternal and fetal heritability for maternal
and neonatal chemokines and cytokines
SIM Dataset Maternal genetics Fetal genetics
h2g SE P value h
2
g SE P value
Chemokines
CXCL10 Mothers 0.79 0.28 4.4 × 10−3 0.99 0.38 5.8 × 10−4
CCL1 Infants 0.72 0.35 2.9 × 10−2 0.98 0.35 1.6 × 10− 2
CCL3 Infants 0.60 0.33 4.6 × 10−2 0.72 0.43 5.0 × 10−2
CCL17 Infants 0.59 0.37 0.09 0.99 0.42 1.0 × 10−2
CCL19 Infants 0.69 0.36 4.0 × 10−2 0.99 0.42 7.8 × 10−3
CCL22 Infants 0.92 0.32 3.8 × 10−3 0.97 0.43 2.0 × 10−2
CCL25 Infants 0.50 0.33 0.07 0.70 0.42 5.0 × 10−2
CXCL5 Infants 0.88 0.34 1.4 × 10−2 0.92 0.43 2.0 × 10−2
Cytokines
IL-4 Infants 0.76 0.37 3.2 × 10−2 0.05 0.49 NS
IL-7 Mothers 0.84 0.28 2.1 × 10−3 0.90 0.37 1.0 × 10−2
NS not significant
Traglia et al. Genome Medicine  (2018) 10:67 Page 6 of 17
cytokines/chemokines measured in the neonates over-
lapped with those measured in maternal serum. After
applying adjustment for a set of maternal and neonatal
confounding factors (described in the ‘Methods’ section)
and exclusion of extreme values (outliers < 7% of the
total individuals, mean = 1%, Additional file 2: Table S3
and Additional file 3: Figure S1), neonates showed
significantly less variance than mothers for the immune
mediators measured in both individuals (F test, P < 0.05)
and particularly tight but approximately normal distribu-
tions and high correlations among most of the immune
mediators (Additional file 2: Tables S3 and S5). We did
not observe any significant correlation (or coefficients
ρ > 0.15) between the 15 cytokines/chemokines mea-
sured in the maternal dataset and the same 15 mediators
measured in the neonatal dataset (Fig. 1). Nor did we
find other correlated maternal-neonatal immune medi-
ator pairs, considering all combinations in case we could
infer a relationship with a non-measured cytokine/che-
mokine (Additional file 2: Table S6).
High fetal heritability regulates the levels of seven neonatal
chemokines
In order to assess whether the infant immune mediator
levels measured at birth might be genetically regulated
independently of the maternal immune system, we mea-
sured SNP-based fetal heritability for 42 neonatal cyto-
kine/chemokine levels after adjustment for potential
confounding factors (including ASD status) via mixed
linear modelling. We were able to identify seven neo-
natal chemokines that showed significant fetal genetic
contribution (heritability = 70–99%; Table 1). To assess
Table 2 Maternal and fetal genome-wide significant association of maternal and neonatal cytokines/chemokines
SNP gen chr A1 MAF Beta SE P value Locus SIM Set P value match-gen
rs12327057 Fetal 18p11 C 0.18 − 0.42 0.07 1.4 × 10−8 ADCYAP1 sIL2R-α M 9.4 × 10−4
rs75885714 Fetal 3p24.3 C 0.08 − 0.53 0.05 8.6 × 10−21 PLCL2 CCL17 I 3.8 × 10−6
rs75885714 Fetal 3p24.3 C 0.08 − 0.48 0.05 3.3 × 10−20 PLCL2 CCL19 I 3.8 × 10−6
rs75885714 Fetal 3p24.3 C 0.08 − 0.36 0.04 2.8 × 10−19 PLCL2 CXCL9 I 5.4 × 10−6
rs75885714 Fetal 3p24.3 C 0.08 − 0.23 0.03 8.2 × 10−13 PLCL2 CCL7 I 1.1 × 10−3
rs75885714 Fetal 3p24.3 C 0.08 − 0.24 0.03 5.2 × 10−12 PLCL2 IFN-γ I 6.0 × 10−3
rs75885714 Fetal 3p24.3 C 0.08 − 0.27 0.04 2.1 × 10−12 PLCL2 IL-2 I 1.5 × 10−3
rs75885714 Fetal 3p24.3 C 0.08 − 0.26 0.04 1.7 × 10−11 PLCL2 IL-6 I 9.7 × 10−4
rs75885714 Fetal 3p24.3 C 0.08 − 0.20 0.03 1.8 × 10−11 PLCL2 IL-10 I 3.8 × 10−4
rs75885714 Fetal 3p24.3 C 0.08 − 0.22 0.03 3.5 × 10−10 PLCL2 IL-1β I 1.4 × 10−3
rs75885714 Fetal 3p24.3 C 0.08 − 0.17 0.03 9.3 × 10−10 PLCL2 CXCL13 I 1.3 × 10−4
rs75885714 Fetal 3p24.3 C 0.08 − 0.16 0.03 2.0 × 10−8 PLCL2 CX3CL1 I 9.8 × 10−4
rs1003645 Fetal 17q12 C 0.28 − 0.63 0.02 2.5 × 10−100 CCL23 CCL23 I 3.4 × 10−24
rs854625 Fetal 17q12 A 0.12 0.47 0.04 4.6 × 10−25 CCL15 CCL15 I 1.1 × 10−6
rs3921 Fetal 4q21.1 C 0.29 0.24 0.03 2.0 × 10−14 CXCL9/10/11 CXCL11 I 1.2 × 10−3
rs16850073 Fetal 4q13.3 T 0.32 0.10 0.02 6.4 × 10−9 CXCL6 CXCL6 I 6.8 × 10−6
rs73359750 Fetal 7q11.23 T 0.08 0.86 0.16 4.9 × 10−8 CCL24 CCL24 I NS
rs41272321 Fetal 3q22.1 G 0.13 − 0.20 0.03 2.8 × 10−10 ACKR4 CCL21 I 3.3 × 10−4
rs2228467 Fetal 3p22.1 C 0.04 0.29 0.05 2.8 × 10−8 ACKR2 CXCL9 I 0.01
rs2228467 Fetal 3p22.1 C 0.04 0.42 0.07 4.4 × 10−9 ACKR2 CCL19 I 0.03
rs2228467 Fetal 3p22.1 C 0.04 0.48 0.07 1.8 × 10−10 ACKR2 CCL17 I 0.02
rs74331971 Fetal 8p23.3 A 0.03 − 0.40 0.07 1.9 × 10−9 FBXO25/TDRP IL-4 I 0.03
rs4303899 Fetal 3q13.32 G 0.12 − 0.09 0.02 1.7 × 10−8 lincRNA CXCL12 I NS
rs115463265 Maternal 3p24.2 T 0.02 − 1.50 0.24 1.6 × 10−9 THRB/RARB CCL11 M NS
rs12778662 Maternal 10p15.1 T 0.07 0.65 0.11 3.7 × 10−9 IL2R sIL2R-α M 0.04
rs1562064 Maternal 4q31.21 G 0.32 − 0.74 0.13 2.1 × 10−8 near SMAD1 IL1-α M 1.5 × 10−3
rs34642455 Maternal 7q22.1 C 0.13 − 2.17 0.38 3.1 × 10−8 CYP3A4 CXCL5 I 3.6 × 10−3
rs72751339 Maternal 15q26.2 T 0.02 − 1.52 0.25 1.3 × 10−8 MCTP2 CCL24 I 1.7 × 10−3
rs17159338 Maternal 5q21.3 C 0.03 − 0.36 0.06 1.2 × 10−9 near EFNA5 IL-16 I NS
gen genetics, chr chromosomal region, A1 tested allele, MAF minor allele frequency, Set dataset, M mothers, I infants and NS not significant
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whether the subset of heritable neonatal chemokines shared
genetic determinants, we calculated the co-heritability
(genetic correlation) between all the possible pairs of the
seven neonatal chemokines, and we compared genetic cor-
relations to linear correlations. We expected that genetic
correlation might be higher than linear correlation if there
were differences in environmental determinants but similar
genetic determinants of both immune mediators. In con-
trast, significantly lower genetic correlations than linear
correlations might indicate a similar response to the shared
environment but distinct genetic determinants involved.
We found seven out of 21 chemokine pairs that showed
significant genetic correlations (ρ > 0.50) and four were sig-
nificantly higher compared to the linear correlations
(Additional file 2: Table S7). Thus, our results allowed us to
define a set of neonatal immune mediators with strong gen-
etic control that includes CCL1, CCL3, CCL17, CCL19,
CCL22, and CCL25. Our results support the hypothesis
that some neonatal chemokines are under strong fetal gen-
etic control early in life.
PLCL2 is a novel fetal locus for several neonatal immune
mediators
Next, we performed genome-wide association studies for
the 42 neonatal cytokine/chemokine levels via linear re-
gression analyses. We observed a SNP (rs75885714,
MAF = 7%) located on chromosome 3p24.3 that was
highly associated with 11 neonatal cytokines and chemo-
kines (Table 2 and Additional file 2: Table S5). The
strongest association was with the chemokine CCL17
(or TARC, β = − 0.53, SE = 0.05, P = 8.6 × 10−21). This
SNP was also associated with a number of inflammatory
cytokines and chemokines: IFNγ, IL-2, CCL7, CXCL9,
and CCL19. We next asked whether the rs75885714
locus is independently associated with each immune me-
diator or whether it drives the regulation of the entire
set of correlated mediators. Regression models including
CCL17 with each other cytokine/chemokine separately
suggest that CXCL9 might independently account for
the association between rs75885714 and the other corre-
lated cytokines/chemokines. To confirm this, we per-
formed a linear regression model for CXCL9 after
including the entire set of ten correlated cytokines/che-
mokines and we still observed a residual association
between rs75885714 and CXCL9. Thus, the association of
the locus with the cytokines/chemokines is driven by
CXCL9 (rs75885714, β = − 0.36, SE = 0.04, P = 2.8 × 10−19),
for which the SNP was responsible for 13% of the total
CXCL9 phenotypic variance. The polymorphism
rs75885714 maps to the PLCL2 gene, which encodes
phospholipase C (Fig. 2a). A second SNP in the same locus
(rs12496141 CXCL9, β = − 0.21, SE = 0.03, P = 1.5 × 10−9;
MAF = 10%; variance explained = 19%) shows high linkage
disequilibrium (LD) with rs75885714 in our dataset
(r2 = 0.68, comparable to LD estimated in Hispanic ances-
try populations included in 1000 Genomes Project [45]
with ENSEMBL [46]; Fig. 2b). After a conditional analysis
using the individual genotypes of rs75885714 as covariate,
the second SNP, rs12496141, showed no association.
A large set of other neonatal immune mediators was as-
sociated with specific fetal loci. Most of the genome-wide
significant loci were near the gene encoding the associated
neonatal cytokine/chemokine or its receptor (Table 2 and
Additional file 3: Figure S2D–H). Additionally, we found
an association with ACKR4 (atypical chemokine receptor
4) and ACKR2 (atypical chemokine receptor 2) loci encod-
ing receptors that serve several chemokines (Table 2 and
Additional file 3: Figure S2I–J).
We identified two additional novel loci genome-wide
significantly associated with immune molecule levels
(Table 2 and Additional file 3: Figure S2K–L) not near
molecule- or receptor-encoding genes: IL-4 levels were
associated with the low-frequency SNP rs74331971 that
maps between FBXO25 and TDRP on chromosome
8p23.3 (β = − 0.40, SE = 0.07, P = 1.9 × 10−9), and the
levels of CXCL12 (or SDF-1) were associated with
rs4303899, located in LINC02024, a long non-coding
RNA on chromosome 3q13.32 between LSAMP and
IGSF11 (β = − 0.09, SE = 0.02, P = 1.7 × 10−8).
Neonatal immune mediators show evidence for maternal
heritability
We performed similar genetic analyses using the 42 neo-
natal cytokine/chemokine levels, but instead of fetal geno-
type data, we substituted maternal genotype data. We
defined the cytokines and chemokines measured in the
neonatal dataset with maternal genetic contribution and
vice versa as ‘cross-heritable’. Six neonatal cytokines and
chemokines showed significant contribution of maternal
heritability, ranging between 60% for CCL3 (or MIP-1α)
and 92% for CCL22 (or MDC). Five of these six were also
neonatally heritable; additionally, the neonatal level of the
cytokine IL-4 was not influenced by fetal genetics but only
by maternal heritability (Table 1). The high standard error
did not allow us to distinguish whether both maternal and
fetal genomes contribute independently or only one indi-
vidual’s genome exerts influence (but the other shares 50%
of alleles by inheritance).
To differentiate between the contributions of the ma-
ternal and neonatal genome, we identified the offspring
alleles not inherited from the maternal lineage at con-
ception (fetal-specific alleles) and the maternal alleles
not transmitted to the offspring (maternal-specific
alleles) (see the ‘Methods’ section) and we calculated
genetic contribution using maternal-specific alleles and
fetal-specific alleles. (Note that we are using haploid ge-
nomes, so significant values are interpreted as evidence
for independent genetic contribution rather than as a
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traditional ‘heritability’ estimate). We observed that
three out of six cross-heritable neonatal cytokine/che-
mokine levels were significantly estimated as controlled
by both maternal and fetal genetics, as well as CXCL5
only by maternal genetics (CCL1 and IL-4 estimate were
not significant; Table 3).
Maternal genome-wide associated loci for the levels of
three neonatal immune mediators
In order to determine whether maternal variation in the
cytokine/chemokine- or receptor-encoding genes associ-
ated with maternal cytokine/chemokines also contributed
to neonatal cytokine/chemokine levels, or whether differ-
ent maternal loci are involved via a separate mechanism,
we mapped specific maternal loci associated with neonatal
cytokine/chemokines levels. We interestingly identified,
via GWAS, three independent low-frequency significant
maternal loci (MAF range 1–3%; P < 3.1 × 10−8) affecting
three neonatal immune mediators. Neonatal levels of
CCL24 were associated with the SNP rs72751339 in
MCTP2 on chromosome 15q26.2. The levels of IL-16
were associated with rs17159338 in the lincRNA
LINC01950 near the EFNA5 gene (Ephrin-A5) on
chromosome 5q21.3. Finally, CXCL5 (or ENA-78) was
associated with rs34642455 in the cytochrome P450 3A4
gene (CYP3A4) on chromosome 7q22.1 (Table 2 and
Additional file 3: Figure S2M–O). CCL24 showed distinct
fetal- and maternal-associated loci whereas IL-16 and
CXCL5 did not show significant fetal loci. These maternal
SNPs were not associated with any maternal immune me-
diator (P < 0.05), except rs17159338 with IL-4 at P = 0.02.
High fetal SNP-based contribution to maternal CXCL10
and IL-7
We also estimated whether the fetal genome affects ma-
ternal mid-gestational circulating cytokine/chemokine
levels. About 99% of the maternal phenotypic variance
of CXCL10 (SE = 37%, P = 5.8 × 10−4) and 90% of IL-7
(SE = 38%, P = 0.02) were explained by fetal heritability,
compared to 79% and 84% maternal heritability esti-
mates, respectively (Table 1). Once again, the high
standard errors did not allow us to distinguish the exact
maternal and fetal contributions or their independence.
Thus, we estimated the proportion of the maternal
circulating cytokine/chemokine levels regulated by
fetal-specific alleles and by maternal-specific alleles.
Maternal IL-7 and CXCL10 levels were significantly reg-
ulated by both maternal-specific alleles and fetal-specific
alleles (Table 3).
Table 3 Maternal-specific allele-based proportion of genetic variance and fetal-specific allele-based proportion of genetic variance
for maternal and neonatal chemokines and cytokines under a no dosage compensation model
SIM Dataset Maternal-only non transmitted allele Fetal-only non inherited allele
V(g)/Vp SE P value V(g)/Vp SE P value
Chemokines
CXCL10 Mothers 0.81 0.19 7.1 × 10−3 0.81 0.20 0.01
CCL1 Infants 0.63 0.31 0.09 0.75 0.26 0.04
CCL3 Infants 0.47 0.40 NS 0.41 0.44 NS
CCL17 Infants 0.75 0.25 0.05 0.81 0.22 0.02
CCL19 Infants 0.80 0.23 0.03 0.83 0.21 0.01
CCL22 Infants 0.95 0.16 2.8 × 10−3 0.83 0.22 0.02
CCL25 Infants 0.48 0.37 NS 0.39 0.44 NS
CXCL5 Infants 0.87 0.20 0.025 0.45 0.41 NS
Cytokines
IL-4 Infants 0.49 0.40 NS 0.00 0.73 NS
IL-7 Mothers 0.79 0.21 0.0163 0.99# 0.17 < 0.01
V(g)/Vp proportion of genetic variance over phenotypic variance
#Fisher’s test applied for non converging models
NS not significant
(See figure on previous page.)
Fig. 2 Linkage disequilibrium regional genomic plot of fetal genome-wide associated SNPs with maternal serum levels of sIL2R-α and 11 neonatal
immune mediators. a Fetal rs75885714 on chromosome 3p24.3 associated with CCL17 (β = −0.53, SE = 0.05, P = 8.6 × 10−21); b The independent fetal
SNP rs12496141 which maps in the PLCL2 gene and (c) Fetal rs12327057 on chromosome 18p11 associated with sIL2R-α maternal levels (β = − 0.42,
SE = 0.07, P = 1.4 × 10−8) maps to a lincRNA ADCYAP1 gene. The x-axis represents the genomic position; the y-axis shows the negative logarithm of the
observed association P value for each tested SNP. Plotted with LocusZoom tool [42]
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One fetal locus contributes to maternal soluble IL-2
receptor levels
We performed genome-wide association analysis using
the fetal genome for each maternal mediator level.
Supporting our heritability evidence of an active role of
fetal genetics on the maternal immune system, the fetal
locus rs12327057 (MAF = 18%) on chromosome 18p11
in RP11-78F17.1, a long noncoding RNA, near
ADCYAP1 (Fig. 2c and Table 2), was associated with sol-
uble maternal interleukin-2 receptor levels (β = − 0.42,
SE = 0.07, P = 1.4 × 10−8). The adenylate cyclase activat-
ing polypeptide 1 gene encodes secreted processed pep-
tides involved in transcriptional activation of target
genes. We did not measure sIL2R-α in neonates so we
are not able to determine whether variation near the
fetal ADCYAP1 gene might affect the neonatal soluble
immune receptor levels. However, maternal sIL2R-α
levels were associated with variation at the IL2RA mater-
nal locus, but not at the fetal IL2RA locus, supporting the
interpretation that both maternal and fetal genetics might
contribute to immune mediator variability, and specifically
that fetal genetics influences maternal cytokines not via
direct transfer of fetal-derived cytokines during pregnancy
but via different pathways. This SNP was not associated
with any neonatal immune mediator (P < 0.05), except
with CCL24 at a nominal level (P = 5.0 × 10−3).
Independent contribution of maternal- and fetal-associated
loci to immune mediator variance
Most of the 17 genome-wide significant loci that were
associated with cytokine/chemokine levels showed
strong association when analysing either the contribu-
tion from fetal or maternal genetics but had reduced as-
sociations when considering paired mother/offspring
genetics. We tested whether at these specific loci, fetal
genetics contributes independently from maternal genet-
ics to maternal immune mediators and whether fetal
genetics contributes independently from maternal genet-
ics to neonatal immune mediators. In nine out of 11
fetal genome-wide significant associated loci with mater-
nal and neonatal immune mediators reported in Table 2,
nominal maternal genetic association was observed; and
in four out of six associated maternal loci with both ma-
ternal and fetal immune mediators, nominally significant
fetal effects were seen (Table 2). When conditioning
each associated immune mediator with both maternal
and fetal genotypes, we observed no residual association
in the mother/offspring with less significant initial evi-
dence for association (Table 2 and Additional file 2:
Table S9). Additionally, most of the maternal top SNPs
(P < =5 × 10−4) do not overlap with the fetal top SNPs
(P < =5 × 10−4) for the same immune mediators
(Additional file 3: Figure S3).
Interleukin-8 and CCL2 levels are associated with ASD outcome
Consistent with previous findings using a quartile analysis
approach in the full EMA sample [34, 47, Heuer LS, Jones
KL, Yoshida CK, Hansen R, Yolken R, Zerbo O, Ashwood
P, de WJ CLAV. An examination of neonatal cytokines
and chemokines as predictors of autism risk: the early
markers for autism study [In preparation]. We observed
two borderline negative associations between maternal
mid-gestational levels of the chemokines IL-8 and CCL2
(MCP1) with ASD (Wilcoxon test, P = 9.3 × 10−3 and
P = 0.02, respectively) and a positive association be-
tween neonatal IL-8 and ASD (P = 8.6 × 10−3) (Table 4
and Fig. 3), after adjustment for the effects of covari-
ates (Additional file 3: Figure S1). No additional sig-
nificant association was detected.
Interleukin-8 levels interact with maternal genotype to
show association with ASD
We hypothesized that the specific genetic factors that con-
tribute to CCL2 and IL-8 might drive the association ob-
served with ASD outcome (Table 4). Since no genome-wide
significant associated loci emerged for CCL2 and IL-8
(Table 2), we selected the most suggestively associated ma-
ternal and fetal SNPs: three maternal SNPs (maternal
CCL2: rs1869714, β = 0.20, SE = 0.04, P = 4.3 × 10−6; mater-
nal IL-8: rs60587996, β = − 0.77, SE = 0.16, P = 3.1 × 10−6,
neonatal IL-8: rs55823040, β = 0.24, SE = 0.05, P = 3.6 ×
10−7) and three fetal SNPs (maternal CCL2: rs17504601, β
= 0.28, SE = 0.06, P = 5.0 × 10−7; maternal IL-8: rs1252145,
β = − 0.66, SE = 0.13, P = 5.3 × 10−7, neonatal IL-8:
rs80166972, β = 0.47, SE = 0.09, P = 4.3 × 10−7). These SNPs
were not themselves associated in logistic models with ASD
outcome (P > 0.1), but we observed a significant interaction
(β = − 0.22 SE = 0.11, P = 0.04) between ASD outcome and
maternal SNP rs55823040 (MAF = 0.09), which was associ-
ated (P = 3.6 × 10−7) with neonatal IL-8 levels. Our analysis
showed that neonatal IL-8 levels were significantly in-
creased only in ASD offspring of mothers with the CT
genotype for rs55823040 (Fig. 4) (few TT homozygotes
were observed). This SNP had only interaction effects and
not main effects with ASD outcome.
Discussion
We report here the first genome-wide multi-approach
study to provide insight into potential patterns of
Table 4 ASD outcome association with CCL2 and IL-8 in mothers
and infants after adjustment for sociodemographic covariates and
for maternal and fetal genetic ancestry
SIM Dataset N Beta SE OR [95% CI] P value
CCL2 Mothers 707 − 0.135 0.058 0.874 [0.78–0.98] 0.019
IL-8 Mothers 707 − 0.243 0.112 0.784 [0.63–0.98] 0.030
IL-8 Infants 649 0.082 0.041 1.090 [1.00–1.18] 0.046
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maternal-fetal genetic control of immune mediator sta-
tus in the prenatal and neonatal periods (Fig. 5). We
discuss specific significant findings, some of which may
be unique to these life stages. In addition, we detail
our observations supporting the interpretation that
cross-genetic associations represent independent mater-
nal and fetal influence on one another and that this in-
fluence occurs via a distinct mechanism rather than
direct exchange of soluble factors.
We showed that the circulating levels of CXCL10
(IP-10) and IL-7 during mid-gestation were strongly reg-
ulated by the maternal genome. These results were con-
sistent with two studies analysing the SNP-based
heritability and twin-based heritability of immune mole-
cules [48, 49]. Many of the immune mediators without
significant estimated genetic contribution showed sig-
nificant GWAS associations, suggesting genetic influ-
ence beyond what we could detect as heritability. We
identified three maternal loci that were potentially in-
volved in mid-gestational immune system status. A SNP
(rs12778662) was associated with soluble levels of IL-2
receptor alpha and maps near the gene encoding IL2RA
(Fig. 5). This association has previously been observed in
healthy adults [8]. In addition, the chemokine CCL11, a
strong activator of eosinophils, was associated with a
novel SNP located between THRB (encoding the thyroid
hormone receptor β) and RARB (encoding retinoic acid
receptor β), which is effective at controlling inflamma-
tory and inducing tolerogenic immune responses. Fi-
nally, maternal levels of the inflammatory cytokine IL1-α
were associated with a novel SNP near SMAD1, which
encodes one of the SMAD proteins involved in the
TGF-β signalling pathway. These latter two associations
were not observed (P > 0.05) in large populations of
healthy adults studied [8].
We also assessed neonatal cytokine/chemokine levels
and their potential genetic control in early life. The re-
duced variance observed in the distributions of neonatal
cytokines suggests that stressful events during birth did
not unduly impact neonatal immune mediator levels,
allowing for the detection of genetic influence.
Moreover, there were low correlations between neonatal
and maternal cytokine/chemokine levels. Although the
samples are taken months apart, should they reflect
baseline genetically-determined levels, we might expect
correlation if neonatal immune mediators were directly
transferred from the maternal bloodstream. Thus, our
observations suggest that maternal cytokines and che-
mokines are not directly populating the neonatal blood
at birth. However, since the neonatal levels reflect both
serum and lysed cells, and the maternal levels were mea-
sured only in serum, the levels measured may not be dir-
ectly comparable. Note that the difference in variation
observed in maternal and neonatal immune mediator
distributions may be biological variation (e.g. influence
of long-term environmental exposure in mothers) or it
may be technical noise (e.g. serum vs. bloodspot or
Fig. 3 Association of maternal CCL2 (a) and maternal (b) and neonatal IL-8 (c) with ASD outcome. The level of each chemokine has been adjusted for the
corresponding set of covariates. The levels of residuals for controls/mothers of controls (light grey) and ASD cases/mothers of ASD cases (dark grey)
are shown
Fig. 4 Neonatal residual levels of IL-8 showed interaction between
ASD outcome and maternal SNP rs55823040. Controls are shown in
light grey, and ASD cases in dark grey. Only CC and CT maternal
genotype categories are shown. Few TT mothers are in EMA sample
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different assay properties); however, either of these ex-
planations are non-genetic and thus will have the same
impact on our genetic analyses.
Genome-wide association analysis identified ten fetal
loci associated with 19 circulating neonatal immune me-
diators at birth (Table 2). We defined a set of six neo-
natal chemokines, CCL1, CCL3, CCL17, CCL19, CCL22,
and CCL25, controlled by shared common fetal genetic
factors. Interestingly, a single large-impact SNP (variance
explained about 13%) rs75885714 was associated with
CXCL9, which drives the association with ten other
highly correlated (ρ > 0.90) neonatal cytokines/chemo-
kines including the heritable CCL17 and CCL19. The
marker rs75885714 maps in PLCL2, which encodes a
phospholipase involved in the regulation of
calcium-protein kinase C signalling pathway. In studies
of Plcl2-deficient mice, it has been shown that Plcl2 acts
as a negative regulator of B cell receptor signalling and
humoral immune responses [50], and in humans is in-
volved in metabolism [51] and implicated in auto-
immune diseases such as psoriasis [52], rheumatoid
arthritis [53], and systemic sclerosis [54]. However, this
is the first study to show PLCL2 associated with
quantitative levels of immune molecules, which could
reflect a developmental observation.
Seven other fetal loci associated with neonatal cytokine
and chemokine levels were located in the gene encoding
the receptor of that cytokine/chemokine. Among these
seven loci, our study found evidence for association with
a cluster of atypical chemokine receptors (ACKRs) and
confirms evidence shown in a recently published study
[8]. The study analysing an adult human population
from Finland showed association between ACKR1 and
ACKR2 and other immune molecules but did not repli-
cate our neonatal finding in ACKR4. Our neonatal EMA
sample replicates at a nominally significant level the as-
sociation of ACKR1 (CXCL11; P = 9.0 × 10–3) in adults,
but we did not replicate all previously-implicated SNPs
[8], likely due to differences between the two studies,
such as the age of the recruited participants and/or the
genetic make-up of the Finnish population.
Finally, two other fetal SNPs were identified in loci not
attributable so far to any known immune function. In
particular, one SNP that was associated with neonatal
IL-4 levels, maps near to TDRP, a gene that encodes a
testis development related protein that is expressed in
Fig. 5 Outline. In the first panel, the diagram of the multi-approach analysis and mechanisms identified are shown. In the second panel, the
serum levels of maternal sIL2-Ra are regulated by maternal genetics through cytokine receptor-encoding gene (IL2RA) and by fetal genetics
through a non-cytokine-encoding gene (ADCYAP1) not previously involved in immune system status
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the thyroid gland and placenta, and has not previously
been associated with immune phenotypes in adults.
Finally, CXCL12 was associated with a SNP in a
lincRNA between LSAMP (limbic system-associated
membrane protein) and IGSF11 (immunoglobulin super-
family member 11), both involved in cell-cell adhesion
and may be important in immune synapse formation.
Although this SNP has not been associated at a
genome-wide significant level with cytokines/chemo-
kines previously, it did show modest signal with several
molecules (Pmin = 8 × 10
−4) [8].
Since the circulating levels of mid-gestational cyto-
kines and chemokines were not correlated with neonatal
levels, we asked whether maternal genetics might dir-
ectly regulate neonatal cytokines/chemokines at birth.
We found significant maternal genetic contribution for
six neonatal immune mediators, suggesting a combin-
ation of independent maternal and neonatal genetic con-
trol for most of those. IL-4 showed only maternal
evidence for heritability. In pregnancy, IL-4 is produced
[55] by immune cells of the placenta, by the maternal
decidua, amniochorionic membranes, cytotrophoblasts,
and both maternal and fetal endothelial cells. IL-4 is an
archetypal cytokine involved in TH2-mediated adaptive
immunity and during pregnancy is thought to help re-
duce the risk of miscarriage. Our result suggests that
neonatal IL-4 levels might be actively regulated by ma-
ternal genetics. However, what those genetic mecha-
nisms are, we were unable to determine. We found only
one maternal SNP (rs7546782) that was significantly
associated with neonatal IL-4 at borderline levels
(P = 7.7 × 10−8) and maps to a region in chromosome 1
that is rich in regulatory elements (see the full set of
summary statistics-level results available at DOI: https://
doi.org/10.5281/zenodo.1321338).
Three maternal GW-associated loci regulate neonatal
mediator levels. The neonatal chemokine CCL24 is asso-
ciated with a maternal SNP in MCTP2, which encodes a
transmembrane protein that binds to Ca2+. MCTP2 is
involved in intercellular signal transduction and synapse
function and potentially metabolic processes as it is as-
sociated with body mass index [56, 57]. Variation near
maternal EFNA5, a member of the ephrin family, is asso-
ciated with the neonatal cytokine IL-16. Ephrin ligands
and receptors are observed in lymphocytes, monocytes,
and dendritic cells, and their expression levels change
during inflammation. Finally, the neonatal chemokine
CXCL5 is associated with a maternal locus in the cyto-
chrome P450 3A4 gene (CYP3A4), one of the most im-
portant effectors of oxidative metabolism in humans.
None of these loci have previously been associated with
adult immune phenotypes [8].
Previous evidence showed that fetal genetics could also
regulate several maternal phenotypes during pregnancy
[10, 11]. In our sample, maternal IL-7 and CXCL10 were
under the control of independent contributions from
maternal-specific and fetal-specific non-overlapping al-
leles. We further identified one fetal locus associated
with maternal sIL2R-α, ADCYAP1, or PACAP, which en-
codes a signalling neuropeptide widely expressed in the
central and peripheral nervous systems. PACAP is also
expressed in different parts of the placenta and the umbil-
ical cord where it affects cell survival, angiogenesis, and
proliferation of trophoblast cells [58]. This locus was not as-
sociated with any fetal cytokine/chemokine, nor has it pre-
viously been associated with adult immune phenotypes [8].
Across our results, the cross-genetic associated loci
map to genes that were not already associated with the
analysed cytokines/chemokines and they showed inde-
pendent association with only maternal or fetal genetics,
but the same locus never showed evidence for both ma-
ternal and fetal effects. As summarized in Fig. 5, our
genetic data suggest that the cross-genetic influence be-
tween mother and fetus is not simply a redistribution of
soluble immune mediators, in which case we would have
expected to see the same loci contributing to the same
mediator in both genetic datasets, and that these would
predominantly encode genes directly relevant to each
cytokine/chemokine or its receptor. Our alternative hy-
pothesis (Fig. 5) is that most of the maternal-fetal impact
occurs via distinct regulatory or indirect placental mecha-
nisms such as signalling at the placental interface and
through a different set of genes than currently implicated
in inflammation. Moreover, these mechanisms could po-
tentially be responsible for the pregnancy-specific regula-
tion of the cytokines/chemokines produced by maternal
and/or fetal placental tissues within the tissues of preg-
nancy [59] and possibly in the peripheral blood.
Finally, we observed that maternal levels of the chemo-
kines IL-8 and CCL2 were significantly lower in mothers
of ASD-affected children compared to mothers of control
children. We also identified a positive association with
neonatal IL-8 levels that is consistent with our findings in
a larger EMA sample. Other studies implicating IL-8 in-
clude measuring IL-8 in the plasma of young (2–5 years
of age) ASD children [19] and one showing increased ex-
pression of the IL-8 gene in brains of ASD children [60].
Interestingly, we demonstrated that the neonatal levels of
IL-8 were significantly associated with ASD outcome only
in children of mothers heterozygous for SNP rs55823040,
which was suggestively associated with overall neonatal
IL-8 levels. This SNP maps near the pseudogene
CACYBPP2, between the nucleoporin NUP35 and the zinc
finger protein ZNF804A, a candidate for ASD, schizophre-
nia [61], and other neuropsychiatric disorders [62]. This
SNP did not show main effects with ASD outcome but
only the observed interaction with IL-8 levels. It will be
important to replicate this finding in additional studies.
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This study has several limitations, including sample
size and lack of information about infection or illness at
the time of sampling. The population sampled also in-
cludes heterogeneous genetic ancestries. While this in-
troduces methodological challenges and does not allow
for heritability estimates precise for a homogenous
population, we have used a number of approaches to en-
sure that our study design did not introduce false posi-
tives into our results. Overall, we believe studying a
representative US population (Southern California) is a
significant strength of this study, as our results are more
likely to be applicable across genetic populations.
Conclusions
Taking advantage of a unique set of mother-infant match-
ing pairs, this study shows patterns of genetic variation
regulating cytokine/chemokine status during pregnancy
and at birth. We identified a total of 17 specific maternal
and fetal loci contributing to one or more cytokine and
chemokine status at the two different time points. Several
of these are novel and may be shown to be specific to
pregnancy and newborn periods upon further study. Our
cross-genetic analysis identified distinct maternal loci in
novel regions independently associated with cytokine/che-
mokine levels in our neonatal dataset and that fetal loci in
novel regions were independently associated with
maternal cytokine/chemokine levels. We speculate that
this pattern of cross-genetic influences at non-cytokine,
non-chemokine, and non-receptor encoding loci and ex-
clusively at loci not previously implicated for adult
immune molecule levels implies a major influence of vari-
ation in placental biology on cytokine and chemokine
levels. Interestingly, the observation of an association be-
tween increased IL-8 and ASD status only in the presence
of a specific maternal SNP genotype suggests that future
studies should consider the cross-genetic interaction in-
volved in early risk for neurodevelopmental disorders.
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